GlassScriptPhysician profile
Casey E Mahoney
NPI 1750829693
$2,776.24
in general payments reported to CMS, 2019-2025
25 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.79 · 2022: $324 · 2023: $836 · 2024: $888 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $448.63 | 2023-2025 | Jot Dx, Cardiomems, Quartet |
| Impulse Dynamics (USA) INC. | $335.00 | 2022-2023 | Optimizer |
| Amgen INC. | $228.02 | 2023-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $193.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $190.78 | 2022-2024 | Farxiga, Wainua |
| Medtronic, INC. | $175.52 | 2023-2024 | Mycarelink |
| Janssen Pharmaceuticals, INC | $146.63 | 2022-2024 | Xarelto |
| Pfizer INC. | $140.39 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $112.94 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.28 | 2022-2024 | Jardiance |
| Bridgebio Pharma, INC. | $94.27 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $88.07 | 2024-2025 | Camzyos |
| Novo Nordisk INC | $84.28 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $72.03 | 2023-2025 | |
| Esperion Therapeutics, INC. | $71.24 | 2024-2025 | Nexletol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $62.49 | 2022-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $48.19 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $37.07 | 2024 | Verquvo |
| Inspire Medical Systems, INC. | $32.74 | 2025 | Inspire |
| Daiichi Sankyo INC. | $23.72 | 2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $20.15 | 2023 | Inpefa |
| Biotronik INC. | $19.18 | 2022 | |
| Amarin Pharma, INC. | $18.65 | 2023 | |
| Terumo Medical Corporation | $14.53 | 2025 | Glidesheath Slender, Tr Band |
| Actelion Pharmaceuticals US, INC. | $14.44 | 2025 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Mahoney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.